 Shares of Kalvista Pharmaceuticals Inc NASDAQ: KALV are sharply higher Tuesday following the release of a mid-Phase clinical readout. What Happened: Kalvista, which focuses on developing small molecule protease inhibitors for diseases with significant unmet need, said KVD900, the most advanced compound in its pipeline, demonstrated statistically and clinically significant efficacy as an oral on-demand treatment for hereditary angioedema, or HAE, attacks in a Phase 2 study. 